Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from INVO Fertility ( (IVF) ).
On July 21, 2025, INVO Fertility implemented a 1-for-3 reverse stock split of its common stock to comply with Nasdaq’s minimum bid price requirement. This adjustment, which consolidated every three shares into one, aimed to maintain the company’s listing on The Nasdaq Capital Market, although compliance is not guaranteed.
The most recent analyst rating on (IVF) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.
Spark’s Take on IVF Stock
According to Spark, TipRanks’ AI Analyst, IVF is a Underperform.
The overall stock score reflects significant financial and technical challenges. The company’s financial performance is marred by losses and high leverage, while technical indicators signal negative momentum. Additionally, valuation metrics highlight market concerns about future profitability.
To see Spark’s full report on IVF stock, click here.
More about INVO Fertility
INVO Fertility is a healthcare services company focused on the fertility market, primarily through assisted reproductive technology (ART) care. The company operates fertility clinics, including INVO Centers, which offer the intravaginal culture (IVC) procedure enabled by the INVOcell medical device. INVO Fertility also engages in the sale and distribution of the INVOcell technology to third-party fertility clinics.
Average Trading Volume: 2,480,780
Technical Sentiment Signal: Sell
Current Market Cap: $1.82M
Learn more about IVF stock on TipRanks’ Stock Analysis page.